海辰药业 reported revenue of ¥0.36B for the period ended 2026-06-30, +18.0% year on year. Net income was ¥0.03B, a 9.0% net margin on a 73.0% gross margin. The largest revenue line is 心脑血管类 at 67% of the total. Free cash flow for the period was ¥-0.02B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.36B | +18.0% |
| Gross profit | ¥0.27B | — |
| Operating income | ¥0.04B | — |
| Net income | ¥0.03B | +13.9% |
| Gross margin | 73.0% | Net margin 9.0% |
| Revenue Q/Q | +27.1% | — |
| Segment | Revenue | Share |
|---|---|---|
| 心脑血管类 | ¥0.25B | 67.4% |
| 锂电池电解液添加剂 | ¥0.09B | 25.0% |
| 抗生素类 | ¥0.01B | 3.9% |
| 免疫调节类 | ¥0.00B | 1.0% |
| 抗病毒类 | ¥0.00B | 0.9% |
| 原料药及中间体 | ¥0.00B | 0.5% |
| 利尿类 | ¥0.00B | 0.5% |
| 其他类 | ¥0.00B | 0.4% |
| 其他(补充) | ¥0.00B | 0.3% |
| 消化类 | ¥0.00B | 0.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.10B | 27.0% |
| R&D | ¥0.01B | 2.7% |
| SG&A | ¥0.19B | 53.2% |
| Tax & other | ¥0.01B | 2.7% |
| Item | Amount |
|---|---|
| Total assets | ¥1.52B |
| Total liabilities | ¥0.40B |
| Shareholders' equity | ¥1.12B |
| Equity / assets | 73.9% |
| Operating cash flow | ¥-0.01B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥-0.02B |
| Cash conversion (OCF / net income) | -3% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
奥联电子 ・ 美联新材 ・ 天铁科技 ・ 熙菱信息 ・ 江龙船艇 ・ 移为通信 ・ 万里马 ・ 华凯易佰 ・ 新雷能 ・ ST朗进 ・ 欧普康视 ・ 利安隆
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies